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Abstract
Background: Duchenne Muscular Dystrophy (DMD) is an X-linked genetic disorder that results
in the production of a dysfunctional form of the protein, dystrophin. The mdx5cv mouse is a model
of DMD in which a point mutation in exon 10 of the dystrophin gene creates an artificial splice site.
As a result, a 53 base pair deletion of exon 10 occurs with a coincident creation of a frameshift and
a premature stop codon. Using primary myoblasts from mdx5cv mice, single-stranded DNA
oligonucleotides were designed to correct this DNA mutation.
Results:  Single-stranded DNA oligonucleotides that were designed to repair this splice site
mutation corrected the mutation in the gene and restored expression of wild-type dystrophin. This
repair was validated at the DNA, RNA and protein level. We also report that the frequency of
genetic repair of the mdx mutation can be enhanced if RNAi is used to suppress expression of the
recombinase inhibitor protein Msh2 in cultures containing myoblasts but not in those heavily
enriched in myoblasts.
Conclusion: Exogenous manipulations, such as RNAi, are certainly feasible and possibly required
to increase the successful application of gene repair in some primary or progenitor muscle cells.
Background
Duchenne Muscular Dystrophy (DMD) is an X-linked
recessive disorder with an incidence of 1 in 3,500 live
born males. It is caused by the dysfunction of dystrophin
(DMD), a large 427 kDa cytoplasmic protein that forms a
link between actin filaments and the dystrophin-glyco-
protein (DGC) complex [1]. The loss of dystrophin is
thought to affect the integrity of the cell membrane lead-
ing to a disruption in cellular calcium homeostasis and
eventually cell necrosis [1-3]. At the genetic level, one-
third of boys afflicted with DMD have point mutations,
insertions or deletions while the remaining two-thirds
have gross deletions or rearrangements within the 2.5 Mb
gene [4] [OMIM #310200 Muscular Dystrophy, Dystro-
phy Type, DMD] and all generally cause a translational
frameshift.
Therapeutic strategies such as gene replacement have been
used to restore protein expression by effectively re-engi-
neering dystrophin cDNA. In addition, attempts have
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been made to introduce smaller functional homologs of
DMD to cells in an attempt to reverse the muscle degrada-
tion process [5-8]. Vectors, which carry these constructs,
however, often elicit an immune response [8,9]. An RNA/
DNA chimeric oligonucleotide (chimera) has been used
successfully to correct the splice site mutation to generate
a genetic alteration in the dystrophin gene, in both ex vivo
and in vivo studies in mouse and dog models of DMD [10-
13]. In a pioneering study, Bartlett et al. [10] showed the
correction of the canine dystrophin gene within skeletal
muscle fibers after injecting the chimera into the cranial
tibialis of Golden Retrievers. The production of wild-type
dystrophin was restored and could be detected for up to
48 weeks at the site of the injection. Rando et al. [11] dem-
onstrated chimera-directed repair of the dystrophin gene
in the mouse extending the results from the dog model;
once again the corrected cells were again localized to the
injection site.
Antisense oligonucleotides also have been used to alter
the splicing of the dystrophin message in a process gener-
ally termed, exon skipping [14-16]. A large number of
exciting reports have demonstrated the feasibility of alter-
ing the splicing patterns of the mutant DMD transcript
[15,17-21]. While this approach is likely to have signifi-
cant therapeutic benefit, the original DMD mutation(s)
remains and thus a continuum of antisense ODN delivery
will be required [22].
When muscle fibers are damaged within the body, a pop-
ulation of quiescent precursor muscle cells, or satellite
cells, become activated myoblasts [23,24], rapidly divide
and initiate the regeneration of the injured muscle [24]. In
the case of DMD, the muscle is thought to be constantly
going through cycles of degeneration and regeneration
due to the instability of the musculature and, therefore,
abundantly populated with myogenic precursor cells.
Thus, an important long term therapeutic approach then
would be to isolate and genetically correct the myoblasts
at the DNA level with subsequent transplantation to the
animal model in order to restore functional dystrophin to
the muscle fibers.
We have begun to develop a more defined ex vivo strategy
in which modified single-stranded oligonucleotides are
designed to repair the mutant dystrophin (ex vivo) in cell
cultures enriched in myoblasts. A current challenge is to
establish a frequency of repair that leads to a level of dys-
trophin expression that can be detected in targeted myob-
lasts. Previously, Bertoni et al. [25] have used fluorescently
labeled oligonucleotides to correct a point mutation in
cells derived from the dystrophic mdx5cv mice. We now
repeat the correction of Dmd point mutation using unla-
beled  modified single stranded oligonucleotides and
establish novel quantitative assays to measure the dys-
trophin production in myoblasts. We also stimulate the
correction reaction by using RNAi against Msh2, a known
inhibitor of the gene repair reaction [26] and observe
higher levels of gene repair.
Results
Isolation of primary cultures from dystrophic mdx5cv mice 
containing myoblasts with determination of isolation 
efficiency
In the natural muscle environment, satellite cells rest in a
quiescent state along the periphery of an intact muscle
fiber. When muscle fibers are damaged, muscle precursor
cells, referred to as myoblasts, divide and fuse with the
damaged muscle fibers to repair them [see [27] for
review]. In order to isolate the muscle precursor cells for
gene repair experiments, muscle tissue was removed from
the limbs of 1 to 3 days old mdx5cv mice, enzymatically
digested and plated. A pre-plating technique was used to
purify these cells from fibroblasts present in the explant
[27,28]. It is known that the fibroblasts adhere to the plate
rapidly, usually within 2 hours, and, therefore, the pre-
plating technique is used them from the culture by passag-
ing the supernatant at a 2 hour time point (PP1) and again
at a 24 hour time point (PP2) [28]. Thus, the supernatant
is passaged until PP4 at which time cells are harvested to
determine the efficiency of myoblast isolation by incuba-
tion with an antibody against desmin (expressed in myob-
lasts). We estimate the efficiency of myoblast isolation in
this experiment to be 53% as determined by counting the
number of desmin positive cells and dividing this number
by the number of total cells observed in multiple fields of
view (data not shown). The remaining 47% are most
likely fibroblasts. Thus, in the experiments outlined
below, we utilize cultures that contain approximately
50% myoblasts and 50% fibroblasts. Primarily myoblasts
are a target because only corrected myoblasts that fuse to
form myotubes will be capable of expressing corrected
dystrophin.
In order to determine the efficiency of gene repair of the
chromosomal dystrophin gene in myoblasts, it was
important to determine the level of transfection of oligo-
nucleotides. Oligonucleotides in varying amounts were
complexed with Fugene 6 to observe the levels of uptake
within the myoblasts. Fugene mediated transfection only
showed a 4–6% uptake of the FAM-labeled oligonucle-
otides (data not shown). Therefore, we chose to use jet-
PEI, which is formulated specifically for delivery of
oligonucleotides to deliver the ODN into the primary cul-
tures. Myoblast cultures were seeded at increasing densi-
ties and lipoplexes composed of 6 μL of jetPEI and 3 μg of
ODN were added to cultures with readout of uptake by
FACS analysis after 24 hours. There was no difference in
the amount of oligonucleotide uptake at different cell
numbers as shown in Figure 1 (average uptake, 36%).BMC Molecular Biology 2009, 10:15 http://www.biomedcentral.com/1471-2199/10/15
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FACS was used to quantify uptake of FAM-labeled oligo-
nucleotide as well as cell death by propidium iodide.
Thus, a range of cell densities can be transfected using the
jetPEI complex.
Gene repair of dystrophin directed by modified single-
stranded oligonucleotides in purified myoblasts from 
mdx5cv mice
The mdx5cv mouse has a point mutation in exon 10, which
creates a splice donor site that results in a 53 base deletion
within the exon (see diagram in Figure 2). This deletion
results in a reading frameshift wherein a premature stop
codon is created 95 bases downstream of the mutation
site. If the ODN directs correction of the base, then the
correct splice pattern is recreated and the 53 deleted bases
remain in the message; in effect, restoring the reading
frame. To evaluate the restoration of the 53 base pair
insertion, a reverse primer was designed to bind to the
deleted portion of exon 10. Thus, amplification can only
occur if the targeted splice site corrected and the full-
length mature message is produced at detectable levels. To
determine the level of expression of dystrophin mRNA
where the deleted region had been restored, mRNA was
reverse-transcribed using a primer specific for exon 12,
which is present in all of the transcripts, corrected or not.
We outlined oligonucleotide-mediated gene repair reac-
tions containing ODNs, mdx47NT or mdx47T, designed
to correct the T substitution mutation within exon 10 of
the dystrophin gene. These are depicted in Figure 2. For
clarity, we provide the wild type and mutant DNA
sequence, as well. The "T" indicates that the 47-mer is
designed to target the transcribed strand while the "NT"
refers to a molecule designed to target the non-transcribed
strand.
The oligos were delivered to myoblasts by jetPEI and the
cells were allowed to recover for 24, 48, 72 and 96 hours
respectively at which point genomic DNA was extracted.
Twenty-five nanograms of DNA were subjected to abso-
lute quantification using the Taqman probe analysis. This
assay measures the amount of wild-type or corrected dys-
Optimization of ODN uptake in primary myoblast cultures from mdx5cv mice Figure 1
Optimization of ODN uptake in primary myoblast cultures from mdx5cv mice. The percent of FAM labeled ODN 
uptake complexed with the transfection reagent jetPEI (blue bars) as a function of the seeding density of the myoblasts is 
shown as well as the amount of background fluorescence when myoblasts are incubated with either the FAM oligo or jetPEI 
alone. The cell density is the 2.5 × 106 when the cells are treated with FAM or jetPEI alone. The amount of cell death at each 
cell density and control samples is also shown (red bars).BMC Molecular Biology 2009, 10:15 http://www.biomedcentral.com/1471-2199/10/15
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trophin DNA within each sample. The probe is designed
to recognize only dystrophin sequences that contain the
changed base and, thus, no direct sequencing of the gene
is necessary to confirm sequence alteration [29]. Figure 3A
shows that wild-type dystrophin can be detected by 24
hours after transfection with either mdx47NT or mdx47T.
The highest amount, 331 pg, a significant 15.72 fold
increase (p < 0.001), is detected when cells are targeted
with mdx47NT. mdx47T corrects less efficiently with an
overall average of 59 pg of wild-type dystrophin detected
from 24 to 96 hours, indicating that there is a strand bias
toward the nontranscribed strand of the dystrophin gene
(Figure 3). PCR products directly from the probe assay
were sequenced to confirm the correction within genomic
DNA and the sequencing results show that the corrected
base (A:red peak) is the major product in the reaction with
a very minor peak (T:green peak) being the uncorrected
mutant base. This minor mutant peak correlates to the
specificity of the probe reaction in that a low level of the
mutant base is detected, but as shown in Figure 3A, this
background is not statistically significant in the quantita-
tion assay.
To evaluate gene repair at the RNA level, quantitative RT-
PCR was carried out using a primer set specific for exon 9
and the deleted portion of exon 10. Table 1 illustrates the
cycle number at which the restored portion of the exon
initially appears. In these analyses, higher Ct values are
equivalent to a lower amount of corrected message while a
lower in Ct values signifies an increase in the presence of
the deleted portion of exon 10. Table 1 shows that the
deleted region is detected at 72 hours of targeting fol-
lowed by 96 hours in DM. A statistically significant 6-fold
increase in message is detected above nonspecific levels.
Taken together, the data indicate that the 47NT is capable
of correcting the dystrophin gene and restoring dys-
trophin expression to the targeted population. Interest-
ingly, the fold increase in correction detected of the
Mutation in dystrophin gene of mdx5cv mice and correcting ODNs Figure 2
Mutation in dystrophin gene of mdx5cv mice and correcting ODNs. Mdx5cv mice have a single point mutation (A to T) 
in the dystrophin gene, which is both bolded and underlined in the gene sequence above. This single base mutation will create 
a donor splice site within exon 10 and cause a 53 base portion of this exon to be spliced out of the mature transcript as 
depicted by the dashed line in the diagram. A frameshift results in a stop codon in exon 11 (*) and will ultimately result in the 
production of a truncated dystrophin protein. Because the natural donor site is still present in the transcript there is a possibil-
ity that some full-length message, containing exon 10 is made and this is shown as the solid line. The ODNs, mdx47T and 
mdx47NT, shown above, were designed to correct the substitution mutation and the target base is underlined.BMC Molecular Biology 2009, 10:15 http://www.biomedcentral.com/1471-2199/10/15
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Quantitative measurement of dystrophin correction in primary cultures containing mdx5cv myoblasts at the DNA level and  sequence analysis Figure 3
Quantitative measurement of dystrophin correction in primary cultures containing mdx5cv myoblasts at the 
DNA level and sequence analysis. A: Total genomic DNA was isolated from targeted myoblasts at various time points, 24 
to 96 hours after introduction of ODNs, mdx47NT or mdx47T. Twenty-five nanograms of this DNA was subjected to abso-
lute quantification by PCR analysis with a FAM labeled probe specific only for the wild-type dystrophin sequence. A standard 
curve had been previously generated using C2C12 (WT) genomic DNA and the amount of wild-type dystrophin has been 
extrapolated from this standard and is presented as nanograms of wild-type dystrophin. These data represent the average of 
three experiments that were analyzed in triplicate. Significance was measured by a Student's t-test and samples were consid-
ered significantly different with a p value of less than *0.05, **0.01, ***0.001. B: DNA sequence reaction of PCR products 
showing the chromatogram representing a mixed population at the targeted base (base 102) with adenine (green/corrected 
base) being the major peak and with thymine (red/mutant base) being a minor population within the reaction.BMC Molecular Biology 2009, 10:15 http://www.biomedcentral.com/1471-2199/10/15
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dystrophin gene detected with the Taqman probe
(15.72×) (see Figure 3A) is not equivalent to the fold
increase in expression (6 fold). A likely explanation for
this observation indicates that some correction is occur-
ring in fibroblasts, which do not express dystrophin,
although such a comparison may not be possible.
The donor splice site in the DMD gene in mdx5cv mice
causes a frameshift which results in a translation of trun-
cated dystrophin protein (10 of the 79 exons). As shown
above, correction of the mutation at the DNA level
resulted in the restoration of intact dystrophin message.
To determine whether the corrected mRNA is translated
into normal dystrophin that contains exon 11, cells were
seeded and once again transfected with mdx47NT or
mdx47T under conditions that provided the highest level
of gene correction. The entire assay was performed in
microscope chambers so that the samples could be
probed directly with an antibody specific for the dys-
trophin protein. Figure 4 reveals the presence of dys-
trophin after a 72 hour recovery and 96 hour
differentiation period, indicating dystrophin is now being
produced within myotubes. Within myotubes that stain
positive for dystrophin, it is evident that the protein is dis-
tributed throughout (see Figure 4B) These data are in
agreement with the western blot analyses performed pre-
viously by Bertoni et al. [25]. Altogether, the data from
DNA, mRNA and protein analyses show that single
stranded oligonucleotides without conjugated chemical
moieties at their termini (i.e. Cy3) correct the dystrophin
gene in cultures containing an enriched population of
myoblasts isolated from dystrophic mice.
Enhancement of dystrophin correction by knockdown of 
Msh2
We and others have shown that a transient knockdown of
the mismatch repair protein Msh2 in repair proficient
cells can increase the overall level of gene repair [26,30].
Msh2 is thought to inhibit the repair reaction through its
action as an anti-recombinase [31,32] by precluding the
binding of the oligonucleotide. Therefore, by knocking
down the levels of this protein, we might predict that the
oligonucleotide will bind more stably to the target site
Table 1: Quantitative measurement of dystrophin, GAPDH, and 
CKM.
Recovery Time
mRNA Transfected ODN 48 hours 72 hours
(Ct value)
Dystrophin mdx47NT 34.1 ± 0.15 33.8 ± 0.22
NS 34.9 ± 0.08 37.1 ± 0.35
GAPDH mdx47NT 13.2 ± 0.08 13.6 ± 0.02
NS 13.3 ± 0.05 13.6 ± 0.32
CKM mdx47NT 22.1 ± 0.11 13.6 ± 0.11
NS 21.5 ± 0.08 13.6 ± 0.10
A quantitative measurement of dystrophin transcripts containing the 
deleted portion of exon 10 was also performed. The cells were 
induced to differentiate with addition of media containing 2% horse 
serum at the indicated time points for 96 hours. Each sample was 
subjected to RT PCR using either dystrophin specific primers or oligo 
dT primers. QPCR was performed using a reverse primer specific for 
the deleted portion of exon 10. GAPDH was used as a loading 
control and CKM levels were measured to ensure similarities in the 
extent of differentiation between samples. Significance was measured 
by a Student's t-test and samples were considered significantly 
different with a p value of less than *0.05, **0.01, ***0.001. mdx47NT 
was used to correct the mutation while nonspecific ODN was used as 
a negative control. GAPDH and CKM were used as positive controls 
with the ODNs in parenthesis added to the mRNA mixtures.
Detection of dystrophin with exon specific antibodies Figure 4
Detection of dystrophin with exon specific antibod-
ies. Cultures containing dystrophic myoblasts were seeded 
in 8 well chambers and were targeted with a 72 hour recov-
ery time after the addition of the either the nonspecific ODN 
(A) or mdx47NT (B). These cells were then allowed to dif-
ferentiate for 96 hours at which point they were fixed and 
incubated with antibody specific for a rabbit polyclonal anti-
body that recognizes dystrophin and a secondary Alexa fluor 
labeled antibody (red). The cell nuclei were stained with 
DAPI, which is shown in blue.BMC Molecular Biology 2009, 10:15 http://www.biomedcentral.com/1471-2199/10/15
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with higher efficiency and facilitate oligonucleotide bind-
ing. In order to determine whether the repair reaction
could be stimulated by knocking down Msh2 in primary
cells, we treated our cultures enriched in myoblasts with
increasing concentrations of RNAi and quantified the
amount of wild-type dystrophin DNA appearing after
incubation with the targeting oligonucleotide for 24
hours. The correction frequency was enhanced 2 and 3
fold at the 1 nM and 10 nM concentrations of the RNAi
(Figure 5). The efficiency decreases at higher concentra-
tions of RNAi presumably due to the elevated levels of
RNAi toxicity often observed in treated cells [33]. The
enriched cell cultures used above were purified further to
obtain myoblasts. This was accomplished by plating the
cells on a collagen coated dish in F10 media. Once conflu-
ency was reached, the myoblasts were detached and sepa-
rated from fibroblasts (etc.); this procedure was carried
our repeatedly until the population of cells in the pooled
culture was predominantly purified myoblast. The steps
in this procedure are illustrated in Figure 6. Panels i and ii
display the enriched culture of cells (i) and after differen-
tiation into myotubes (ii); the arrows point to fibroblasts.
In panels (iii) and (iv), the purified myoblast culture is
illustrated before (i) and after (ii) differentiation into
myotubes. Panels (v) and (vi) display cells in dark field
after staining with Desmin (red). The fact that the vast
majority of cells are stained in panel (vi) indicated that
differentiation into myotubes has occurred. Thus, the pro-
cedure has enabled the isolation of a purified culture of
myoblasts that can be targeted with the oligonucleotide.
The mdx47NT ODN was introduced using jetPEI into a
purified myoblast culture at various doses (the N/P ratio
was kept at 5) and incubated for 24 hours. Genomic DNA
was isolated and RT-PCR performed to analyze the sam-
ples for gene repair. We observed a clear dose response by
calculating the amount of wild-type DNA emerging in
treated samples (Figure 7) as compared to a standard
curve (see Methods and Materials). The data suggest that
a wild type dystrophin allele is present in at least some of
the myoblasts where gene repair should have taken place.
While it is not a perfectly sound comparison, the levels of
gene repair in the enriched cultures and the purified cul-
tures are approximately equivalent at the 24 hour time
point (mdx47NT). Interestingly, the background level
from the untreated control samples is higher in the puri-
fied myoblasts than in the enriched culture.
Since RNAi-directed Msh2 knockdowns had elevated cor-
rection efficiencies in myoblast-enriched cultures, we
applied this strategy to cultures of purified myoblasts
where active conversion was shown (above) to take place.
Purified myoblast cultures were treated simultaneously
with various doses of the RNAi used in the experiments
presented in Figure 5 and either 0.3 μg, 0.6 μg or 0.9 μg of
targeting ODN, mdx47NT. The fold change in the evolu-
tion of wild type dystrophin DNA was measured after 24
hours and the results are presented in Figure 8A, B and 8C,
respectively. No statistically significant difference in cor-
rection activity is observed at any RNAi level, although a
clear reduction in Msh2 RNA levels is taking place (Figure
9). These data differ from the results reported in Figure 5
suggesting perhaps that enhancement of gene repair by
RNAi may not have been occurring in myoblasts.
Discussion
Successful correction of the dystrophin gene using either
the RNA/DNA chimera or the modified single stranded
oligonucleotide has been achieved in both dogs and mice
by direct injection of synthetic DNA molecules [10-
12,25]. The frequency of correction throughout muscle tis-
sues however must be increased to enable therapeutic
benefit. Bertoni et al. [25] have demonstrated that when
muscle is injected directly with synthetic oligonucle-
otides, genetic correction was restricted to the dystrophin
gene within a population of satellite cells. Since the fre-
quency of gene repair is higher when delivery to cells out-
side the body takes place in an ex vivo approach. Thus, a
more efficient approach for the treatment of DMD might
entail using ex vivo delivery with subsequent transplanta-
tion back into the host.
To enable this ex vivo strategy, it was essential to optimize
the efficiency of ODN delivery and ODN-mediated cor-
rection of myoblasts. This was accomplished by transfect-
ing a culture of primary muscle cells enriched in
myoblasts with a FAM labeled oligonucleotide and meas-
uring uptake by FACs analysis. We confirmed that the
ODN was present in the nucleus by examining the nuclei
with confocal imaging (data not shown). Correction of
the point mutation in the dystrophin gene was then dem-
onstrated at the level of DNA, RNA and protein. Analysis
of the quantity of corrected DNA indicated that the correc-
tion frequency remains stable over the course of 96 hours
when targeting with either mdx47NT or mdx47T. A signif-
icant increase in message containing the portion of exon
10 deleted in the mutant cells was also detected at both 48
and 72 hours after transfection. There was no reduction in
the level of repaired RNA over time which suggests that
the corrected gene produces stable and inheritable mes-
sage.
DNA analyses indicate that correction occurs at a 3 fold
higher frequency when the nontranscribed strand of the
gene is targeted. One hypothesis for strand bias is that the
movement of RNA polymerase would interrupt the pair-
ing of the ODN and this would result in lowered correc-
tion efficiency [34]. The dystrophin gene, however, is
expressed only in differentiated cells and therefore, ODN
binding stability should not be disrupted by the move-BMC Molecular Biology 2009, 10:15 http://www.biomedcentral.com/1471-2199/10/15
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Enhancement of Dystrophin repair by knockdown of Msh2 Figure 5
Enhancement of Dystrophin repair by knockdown of Msh2. A: Myoblasts derived from mdx5cv mice were co-trans-
fected with various amounts of RNAi specific to knockdown Msh2 and 3 μg of correcting oligonucleotide mdx47NT. Total 
genomic DNA was isolated after 24 hours and 25 ng were subjected to absolute quantification using a FAM labeled probe spe-
cific only for wild type dystrophin. The fold change in wild-type dystrophin was determined from three independent experi-
ments assayed in triplicate and significance was deciphered by a student's t-test. Differences were considered significant only 
when the p < 0.05. B: Knockdown of Msh2 by RNAi. Myoblasts were co-transfected with various amounts of RNAi specific to 
knockdown Msh2 and 3 μg of correcting oligonucleotide mdx47NT. Total mRNA was isolated after 6 hours and subjected to 
RT-PCR.BMC Molecular Biology 2009, 10:15 http://www.biomedcentral.com/1471-2199/10/15
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Dystrophin repair in purified cultures of myoblasts Figure 6
Dystrophin repair in purified cultures of myoblasts. Purification of the primary cultures of myoblasts. (i) enriched cul-
ture of myoblasts. The cultures were derived from limbs of Mdx5cv mice, and population of the myoblasts was enriched using 
pre-plating technique (see "Materials and Methods); (ii) myotubes in the enriched culture. The enriched cultures were induced 
to differentiation by culturing in differentiation medium. The arrows show representative fibroblasts; (iii) purified culture of 
myoblasts. The enriched cultures were subjected to pre-plating repeatedly until fibroblast-like cells were not observed in cul-
tures. The purified cultures were cultivated in F10-based medium; (iv) myotube in the purified culture. The cultures were 
induced to differentiation by culturing in differentiation medium; (v) and (vi) desmin staining of the purified culture. Cell nuclei 
were counter stained with DAPI (v; blue). All of the observed cells were positive for desmin staining (vi; red).BMC Molecular Biology 2009, 10:15 http://www.biomedcentral.com/1471-2199/10/15
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ment of the RNA polymerase. Alternatively, the orienta-
tion of the gene in terms of the general direction of
replication fork movement can influence the targeting fre-
quency in that the lagging strand targets at a higher level
than the leading strand [35]. Thus, the strand designated
as nontranscribed may also be the lagging strand at the
target site.
Previous experiments of Ferrara and Kmiec [36] show that
the corrected cells reduce their cell division cycle after
introduction of the oligonucleotide because the free DNA
ends activate G2 checkpoint proteins. During this time,
the uncorrected population is able to divide, which will,
in effect, cause the number of corrected cells to be diluted
in number. This results in a lower measure of correction
efficiencies as division in the uncorrected population is
not impaired. In primary myoblasts cultures, however,
this does not seem to be the case as the whole population
of cells continues to divide with the correction efficiency
maintained. This observation suggests that the corrected
cells do not suffer a growth disadvantage by this ex vivo
protocol.
Duchenne Muscular Dystrophy (DMD) is caused by an
absence of the protein dystrophin as indicated by the
absence of immunostaining for this protein in most of the
muscle fibers. We observed elevated levels of dystrophin
in cells that were treated with specific ODNs designed to
correct the mutated dystrophin gene and after introduc-
tion of the oligonucleotide, myotubes that are expressing
a significant amount of dystrophin are detected at 72
hours. The number of corrected cells that contribute dys-
trophin to the positive myotubes is unknown, but it is
interesting to note that each myotube that stained positive
had dystrophin evenly distributed throughout. This indi-
cates that the dystrophin produced by the corrected gene
can diffuse throughout a small myotube in vitro and
would probably diffuse though part of a myofiber in vivo,
in a region called the nuclear domain [37]. The long-term
goal of the present study is to transplant corrected myob-
lasts back into mice to restore dystrophin production in
muscle fibers. To achieve this goal it was necessary to
establish ex vivo targeting conditions wherein the highest
level of correction frequency in purified cells is achieved.
The observation that Msh2 knockdown enhanced the
repair frequency also indicates that the mechanism of
gene repair is conserved in primary cells and has, to some
degree validated basic studies in established model sys-
tems [38]. To our surprise, RNAi knockdown of Msh2 in
cultures of purified myoblasts did not lead to an elevation
in the repair of the mutant dystrophin gene, regardless of
increasing amounts of correcting ODN at the varying
Dystrophin correction in the purified cultures of myoblasts Figure 7
Dystrophin correction in the purified cultures of myoblasts. Various amounts of mdx47NT were transfected to puri-
fied myoblasts. Total genomic DNA was isolated after 24 hours, and 25 ng of this DNA was subjected to absolute quantifica-
tion using a FAM labeled probe specific only for wild type dystrophin.BMC Molecular Biology 2009, 10:15 http://www.biomedcentral.com/1471-2199/10/15
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Effect of Msh2 knockdown on dystrophin correction in purified myoblasts Figure 8
Effect of Msh2 knockdown on dystrophin correction in purified myoblasts. Purified myoblasts were co-transfected 
with various amounts of RNAi specific to knockdown Msh2 and (A) 0.3 μg, (B) 0.6 μg or (C) 0.9 μg of correcting oligonucle-
otide (mdx47NT), respectively. Total genomic DNA was isolated after 24 hours and 25 ng were subjected to absolute quanti-
fication using a FAM labeled probe specific only for wild type dystrophin. The fold change in wild-type dystrophin was 
determined from three independent experiments assayed in triplicate.BMC Molecular Biology 2009, 10:15 http://www.biomedcentral.com/1471-2199/10/15
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doses of RNAi. The overall level of correction in the puri-
fied cultures is substantially lower and may be at a basal
level where adjuvant treatments designed to stimulate
activity do not impact the gene repair reaction. In addi-
tion, these results suggest that the stimulation of correc-
tion in the enriched cultures was likely taking place in the
fibroblasts which contaminate the culture. For unknown
reasons, primitive progenitor cells are less amenable to
gene repair or at least provide an environment, less con-
ducive for the reaction.
Correction levels vary among cell types with certain
mutant targets being repair at levels approaching 1–5%.
Yet, the consensus view is that progenitor cells, at any step
along the differentiation pathway, do not enable this reac-
tion to take place efficiently [39-41]. A series of natural
barriers seems to exist in these cell types including lower
transfection efficiencies and dosage-dependent toxicity.
Increasing the amount of ODN introduced into the cell
usually results in a gradual increase in side effects [39].
Progenitor cells are usually more sensitive to the transfec-
tion agent [42] and strand bias for targeting can also vary
widely based in gene types [43]. Murphy et al. [39] found
a mismatch hierarchy that contributed to the various lev-
els of gene correction; A:G > A:A > A:C. If this is true, then
the capacity to target progenitor cells will be hampered.
Such a hierarchy has not been observed in somatic cell tar-
geting where correction efficiencies are generally higher.
Conclusion
Thus, progenitor cells will present unique challenges that
will require exogenous manipulation to elevate frequency
of gene repair. While MSH2 knockdown appears not to be
a sufficient protocol to meet this goal in myoblasts, it does
not mean that other progenitor lineages will not response
positively. In fact, Dekker et al. [41] have already shown
that MSH2 knockdown does increase the frequency of
gene repair in mouse ES cells. More recently, Aarts et al.
[30] provided support and confirmed these observation
and Maguire and Kmiec [26] extended this protocol suc-
cessfully into mouse embryonic fibroblasts. Morozov and
Wowrousek [44] followed among the same theme with
observations that inhibition of Rad51/54 and Ku70/86
led to an increase in gene correction efficiency. These
types of cellular manipulations are certainly feasible and
may be required for the successful application of gene
repair in primary or progenitor cells.
Methods
Cells and oligonucleotides
Primary myoblasts derived from the mdx5cv mice were
maintained in DMEM supplemented with either 10% or
20% FBS. When the cells were induced to differentiate,
DMEM containing 2% horse serum (DM) was added to
the cells for at least 96 hours. The mutation of the parental
plasmid pEGFP N3 to create the mutant pEGFP N3 (rep)
has been described previously [38]. Targeting oligonucle-
otides, eGFP3S/47NT, mdx47NT, mdx47T, and
mdx47NT-FAM were obtained either from Sigma Genosys
(St. Louis, MO) or IDT (Coralville, IA) where they were
synthesized and purified by HPLC before distribution. All
modified single-stranded oligonucleotides were resus-
pended to a concentration of 200 μM and aliquots were
stored at -20°C. The mdx5cv mice were obtained from the
Jackson Laboratory.
Isolation of myoblasts from newborn mdx5cv mice
The isolation procedure for mouse myoblasts and subse-
quent pre-plating methods have been described previ-
ously [27,28]. This work was authorized by the Laval
University Animal Care Committee and experiments were
conducted in accordance with guidelines set forth by the
Canadian Council of Animal Care. Briefly, limbs of 1 to 3
days old male mdx5cv mice were isolated and muscle was
pulled from the bone and cartilage using sterile forceps.
The muscle was treated for 1 hour with Collagenase
(Sigma, St. Louis, MO) and Dispase II (Roche, Indianapo-
lis, IN) to degrade collagen and to disrupt cell contacts.
The cells were plated for 2 hours to allow fibroblasts,
which rapidly adhere, to attach to the petri dish (PP2).
The supernatant, containing a mixture of myoblasts and
fibroblasts, was removed and the cells are passaged again
to another petri dish (PP3). After 24 hours the cells were
again passaged (PP4) and subsequently transferred to
another culture dish (PP5). Purified myoblasts were
expanded and used in gene repair experiments.
Immunocytochemistry
Cells were aliquoted into 4 wells of an 8 well chamber at
a density of 1 × 105 cells, and allowed to attach overnight.
Knockdown of Msh2 by RNAi Figure 9
Knockdown of Msh2 by RNAi. Purified myoblasts were 
co-transfected with various amounts of RNAi specific to 
knockdown Msh2 and 0.75 μg of correcting oligonucleotide, 
mdx47NT. Total mRNA was isolated after 6 hours and sub-
jected to RT-PCR.BMC Molecular Biology 2009, 10:15 http://www.biomedcentral.com/1471-2199/10/15
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The cells were fixed using 100% ethanol for 5 minutes at
-20°C, permeabilized with 0.1% Triton X-100, and then
incubated with either desmin (Sigma, St. Louis, MO) spe-
cific or dystrophin specific antibodies raised in rabbit
(Abcam, Cambridge, MA 1:1,000) at room temperature
(RT) for 1 hour or overnight at 4°C. After washing the
cells, a secondary goat α-rabbit antibody conjugated to a
Cy3 fluorophore (desmin) (Zymed Laboratories, San
Francisco, CA) or an Alexa 546-coupled goat anti-rabbit
antibody (Molecular probes 1:1500) was added to the
wells and this mixture was incubated with agitation for 1
hour at room temperature. After four 15 minute washes,
the wells were dried and mounting media containing
DAPI was added to each well (Molecular Probes, Eugene,
OR). The cells were then visualized using a Zeiss™ inverted
100 M Axioscope equipped with a Zeiss™ 510 LSM confo-
cal microscope with a coherent krypton argon laser (30
mW) containing 488 nm or 568 nm and 742 nm excita-
tion lines.
Gene repair of dystrophin in purified myoblasts
Cells were plated in 6-well culture dishes at a density of 1
× 105 with media containing 20% FBS. jetPEI was used to
make oligonucleotide complexes with 3 μg of ODN at an
optimal N/P ratio (nitrogen/phosphate ratio) of 5. This
reagent was added to 1 ml of media and the cells were
incubated for various amounts of time at which point dif-
ferentiation media (DM) was added; the cells were differ-
entiated for 96 hours, then harvested for FACS analysis
and genomic DNA isolation. For mRNA analyses, the cells
were collected at least four days after the addition of DM
containing 2% horse serum.
Knockdown of Msh2
RNAi, designed to knock down Msh2, was purchased
from Ambion (Ambion, Austin, Texas); siRNA (ID#
155431) is designed to anneal to the mouse MSH2 RNA
at exon 3 NM_008628. During the targeting experiments,
the RNAi was mixed with the correcting oligonucleotides
complexed with jetPEI and added to the cells as described
above.
Co-transfection ssODNs and Msh2 RNAi
Cells were plated in 6-well plates at a density of 1 × 105
cells/well with growth media (DMEM supplemented with
20% FBS, penicillin and streptomycin). Twenty four hours
after plating, cells were co-transfected 3 μg of mdx/47NT
and RNAi specific to knockdown Msh2 (0–200 nM). Sev-
enty two hours after transfection, the growth media were
replaced by differentiation media (DMEM supplemented
with 2% horse serum, penicillin and streptomycin), and
the cells were maintained in differentiation media for 96
h. Total RNA was isolated from the cells, and reverse tran-
scription and quantitative PCR were conducted as
described in "RNA isolation and, RT PCR and quantitative
PCR.
Msh2 RNAi
Cells were plated in 6-well plates at a density of 1 × 105
cells/well with growth media. Twenty four hours after
plating, cells were co-transfected 3 μg of mdx47NT and
RNAi specific to knockdown Msh2 (1–100 nM). Total
RNA was isolated 3 or 6 h after transfection Methods of
reverse transcription and quantitative PCR were same as
"RNA isolation and, RT PCR and quantitative PCR",
except for primers: musMSH2/257F 5' agaccctgcagagtgtt-
gtgctta 3'; musMSH2/1010R 5' tgagagccagtggtgtcttcaaca 3'
or mouse GAPDH4FwQ 5' tgtctcctgcgacttcaacagc 3';
GAPDH5RevQ 5' atgtaggccatgaggtccacca 3'.
RNA isolation, RT PCR and quantitative PCR
After differentiation of the myoblasts, the cells were har-
vested by trypsinization and collected by centrifugation at
1,500 rpm for 7 minutes. After washing with 1× PBS, the
RNA was extracted using a Qiagen RNA extraction kit
(Qiagen, Valencia, CA) according to the manufacturer's
instructions. Three hundred nanograms of RNA was sub-
jected to reverse transcription to generate cDNA using a
gene specific primer Rev-ex12 5' cag gtc caa agg gct ctt cc 3'
or primer oligo dT using the first strand synthesis kit (Inv-
itrogen, Carlsbad, CA). Five microliters was added to a 20
μL mixture of 2× Sybrgreen Master Mix (Applied Biosys-
tems, Foster City, CA) with 2.5 μM of each primer:
Forw-ex 9 5' gtt atg cct tca cag gct gc 3'; Rev-ex10 in 5'cacttc
ttc aac atc att tg3' or GAPDH4FwQ 5'tgtctcctgcgacttcaacag
c3'; GAPDH5RevQ 5'atgtaggccatgaggtccacca 3' CKM F1 5'
GCAACACCCACAACAAGTTCA 3' and CKM R1 5'
TGTCTCCTTATCGCGAAGCTT 3'. Samples were added to
each well of a 96 well plate in duplicate for each primer
set. Dystrophin was amplified using the cDNA generated
by the gene specific primer and GAPDH or CKM from
cDNA generated using oligo dT. QPCR was run for 1 rep-
etition at 50°C for 2 minutes, 1 repetition at 95°C for 10
minutes, 40 repetitions at 95°C for 15 seconds and 40
repetitions at 59°C for 1 minute with data collection at
step 1 of stage 3. Upon completion of PCR, the threshold
and baseline values were set to measure Ct values at the
beginning of the exponential amplification. Ct values
from 3 experiments were averaged per sample and sub-
jected to a student's t-test and ANOVA to determine signif-
icance.
DNA isolation and absolute quantification by PCR
Cells were harvested and collected by centrifugation at
1500 rpm for 7 minutes and washed twice with 1× PBS or
lysed directly in a tissue culture dish after washing with 1×
PBS. DNA was precipitated using the genomic wizard
DNA extraction kit as instructed by the manufacturerBMC Molecular Biology 2009, 10:15 http://www.biomedcentral.com/1471-2199/10/15
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(Promega, Madison WI). Twenty-five nanograms of
genomic DNA was added to a total of 7 μL of water and
this was mixed with 13 μL of a 2× PCR master mix, 50 nM
of a 6FAM labeled probe specific to bind to wild-type dys-
trophin 5'FAMcac aag gag aga ttt3', 900 nM of forward
primer mdx5cvasF 5' ttt ctg ccg agg ata cat tgc3' and 900
nM of reverse primer ex 10 out 5' ctc atg agc atg aaa ctg ttc
3'. Each experimental protocol was run in triplicate. A
standard curve was generated using 50 ng, 25 ng, 12.5 ng,
6.25 ng, and 3.13 ng of genomic DNA isolated from
C2C12 cells, which are wild-type for dystrophin. As a sep-
arate control, reaction mixtures containing 25 ng of
genomic DNA from mdx5cv were used to determine the
background of wild-type DNA in each experiment. PCR
conditions were: 1 repetition at 50°C for 2 minutes, 1 rep-
etition at 95°C for 10 minutes and 40 cycles of 95°C for
15 seconds and 60°C for 1 minute. The data were col-
lected at stage 3 of step 1. Threshold and baseline levels
were set to measure the Ct values at the lowest level of
exponential amplification and the average mean was
determined from each experiment. Statistical significance
was determined by a student's t-test and was considered
significant only if p was less than 0.05. Following the PCR
amplification the products were purified using Qiagen's
QIAquick PCR purification kit according to the instruc-
tions and submitted for sequencing using the mdx5cvasF
primer.
Primary mouse myoblast purification
The enriched culture obtained from Tremblay lab was
plated on a collagen-coated culture dish with F10 nutrient
mixture (Invitrogen, Carlsbad, CA) supplemented with
10% (v/v) FBS, 2.5 ng/ml bFGF (Promega, Madison, WI),
100 U/ml penicillin and 100 mg/ml streptomycin. When
the culture reached confluency, cells were detached from
the dish without using trypsin. To accomplish this, the
dish was washed with PBS after aspiration of medium,
incubated with a small amount of PBS at room tempera-
ture for 5 min, and hit firmly sideways. Predominant cell
type in the detached cells was myoblast due to the fact that
myoblasts are likely to detach from collagen-coated dish
than fibroblasts are. The detached cells were collected
with F10 nutrient mixture, plated on a new collagen-
coated dish, and expanded. The above procedures were
repeated until no fibroblasts were observed in the culture.
Upon completion of purification, medium was switched
F10 growth medium to F10/DMEM (1:1) supplemented
with 10% (v/v) FBS, 2.5 ng/ml bFGF (Promega, Madison,
WI), 100 U/ml penicillin and 100 mg/ml streptomycin.
Desmin staining
Cells were plated on 2-well chambers at a density of 8 ×
104 cells/well and incubated at 37°C overnight. The cells
were fixed using ethanol for 5 minutes at -20°C, permea-
bilized using 0.3% (v/v) TritonX for 10 minutes at room
temperature, blocked using 5% (v/v) heat-inactivated
goat serum for 30 minutes at room temperature, and then
incubated with desmin specific antibody (Sigma, St.
Louis, MO; dilution, 1:50) for 1 hour at room tempera-
ture. After washing the cells, a secondary goat a-rabbit
antibody conjugated to Cy3 (Zymed laboratories, San
Francisco, CA; dilution, 1:750) was added to the wells and
this incubated with agitation for 1 hour at room tempera-
ture. After four 15 minute washes, the wells were briefly
dried and mounting media containing DAPI was added to
each well (Molecular Probes, Eugene, OR).
Oligo dose experiment
Purified myoblasts were plated in 6-well plates at a den-
sity of 1.5 × 105  cells/well with F10/DMEM growth
medium 24 hours before transfection. jetPEI was used to
make oligonucletide complexes with various amounts of
mdx47NT at N/P (nitrogen/phosphate) ratio of 5. This
reagent was added to 1 ml of media and the cells were
incubated. Genomic DNA was isolated 24 hours after
transfection using masterpure DNA purification kit (Epi-
centre, Madison, WI). TaqMan® probe-based real time
PCR was performed to quantify wild type dystrophin.
Probe specific for wild type dystrophin (5'-FAMcac aag gag
aga ttt-3') were used with the primer pair: forward primer,
5'-ttt ctg ccg agg ata cat tgc-3'; reverse primer, 5'-ctc atg agc
atg aaa ctg ttc-3'. Real time PCR was performed with 25 ng
genomic DNA, 900 nM both forward and reverse primer,
and 250 nM probe in each 20 ml reaction. A standard
curve was generated using 1, 0.5, 0.25, 0.125, 0.0625 ng
of genomic DNA isolated from C2C12 cells, which have
wild type dystrophin gene. PCR conditions were: 1 repeti-
tion at 50°C for 2 minutes, 1 repetition at 95°C for 10
minutes and 40 cycles of 95°C for 15 seconds and 60°C
for 1 minute. Each experimental protocol was run in trip-
licate.
Co-transfection ssODNs and Msh2 RNAi
Purified myoblasts were plated in 6-well plates at a den-
sity of 1.5 × 105  cells/well with F10/DMEM growth
medium 24 hours before transfection. Cells were co-trans-
fected 0.75 mg of mdx47NT and siRNA for Msh2 knock-
down (0–100 nM) using jetPEI. Twenty four hours after
transfection, genomic DNA was isolated, and TaqMan®
probe-based real time PCR was performed to quantify
wild type dystrophin as described above ("Oligo dose
experiment")
Msh2 RNAi
Purified myoblasts were plated in 6-well plates at a den-
sity of 1.5 × 105  cells/well with F10/DMEM growth
medium 24 hours before transfection. Cells were co-trans-
fected 0.75 mg of mdx47NT and siRNA for Msh2 knock-
down (0–100 nM) using jetPEI. Total RNA was isolated 6
hours after transfection. Two hundred nanograms of RNABMC Molecular Biology 2009, 10:15 http://www.biomedcentral.com/1471-2199/10/15
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was subjected to reverse transcription to generate cDNA
using the first strand synthesis kit (Invitrogen). Five
microliters was added to a 20 ml mixture of 2× Sybergreen
master mix (Applied Biosystems, Foster City, CA) with 2.5
mM of each primer: musMSH2/257F 5' agaccctgcagagtgtt-
gtgctta 3'; musMSH2/1010R 5' tgagagccagtggtgtcttcaaca 3'
or mouse GAPDH4FwQ 5' tgtctcctgcgacttcaacagc 3';
GAPDH5RevQ 5' atgtaggccatgaggtccacca 3'. Samples were
added to each well of a 96 well plate in duplicate for each
primer set. QPCR was run for 1 repetition at 50°C for 2
minutes, 1 repetition at 95°C for 10 minutes, 40 repeti-
tions at 95°C for 15 seconds and 40 repetitions at 59°C
for 1 minute with data collection at step 1 of stage 3. Upon
completion of PCR, the threshold and baseline values
were set to measure Ct values at the beginning of the expo-
nential amplification. Ct values from 3 experiments were
averaged per sample.
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